tbuckley/cabot-search huggingface dataset:
Athlete abuse hurts everyone: vicarious and secondary traumatic stress in sport
Authors: Yetsa A Tuakli-Wosornu, Michael Amick, Amos N Guiora, Sarah R Lowe
Journal: British Journal of Sports Medicine (2021)

procedures as essential (prioritised), desirable (advanced) or optional (aspirational), and the formal inclusion of an acute sports trauma evaluation to aid critical decision-making.In one of a number of appendices, milestones are suggested to assess competency.These milestones now recognise the importance of identifying pathology and performing procedures, and also generating a detailed and accurate report.A useful example of an objective structured clinical examination for the assessment of trainees is also included. THE NEXT LEVEL IS HERE…In 2010, Drs Kim Harmon and Fran O'Connor penned a BJSM editorial "Musculoskeletal ultrasound: taking sports medicine to the next level," describing a structured AMSSM curriculum and supportive courses such as preconference offerings that have become a highlighted feature of annual AMSSM meetings. 9A decade later, it is fair to say that the 'next level' has certainly been attained, with an expanded curriculum supported by a growing field of qualified faculty and a rich repository of freely accessible resources (AMSSM online material).
1436TiP Trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-positive gastric cancer (GC) or gastroesophageal junction (GEJ) adenocarcinoma who have progressed on or after a trastuzumab-containing regimen (DESTINY-gastric04, DG-04): A randomized phase III study
Authors: K. Shitara, J. Seraj, F.A. Franke, Y. Kawaguchi, L. Shen, T. Kamio, G. Meinhardt, J. Tabernero
Journal: Annals of Oncology (2021)
1563MO CoVigi phase IV multicentric trial evaluating COVID-19 vaccination adverse events and immune response dynamics in cancer patients: First results on antibody and cellular immunity
Authors: R. Obermannova, R. Demlova, I. Selingerova, M. Doubek, D. Okrouhlicova, M. Mlnarikova, K. Pilatova, J. Nevrlka, H. Lejdarova, B. Weinbergerova, Z. Cermakova, D. Valik, J. Mayer, I. Kiss, L. Zdrazilova-Dubska
Journal: Annals of Oncology (2021)
A prolonged, nationwide measles outbreak despite very high vaccination coverage in Israel, 2018-19
Authors: Emilia Anis, Eric J Haas, Viki Indenbaum, Sheperd Roee Singer, Bruce Warshavsky, Shmuel Rishpon, Manfred S Green, Ella Mendelson, Itamar Grotto, Ehud Kaliner, Siegal Sadetzki
Journal: Journal of Infection (2021)
663P First-line nivolumab + cabozantinib vs sunitinib in patients (pts) with advanced renal cell carcinoma (aRCC) in subgroups based on prior nephrectomy in the CheckMate 9ER trial
Authors: C.G. Porta, M. Burotto, C. Suarez Rodriguez, M.T. Bourlon, J. Hsieh, A.Y. Shah, A. Hamzaj, J. Bedke, D. Pook, E.R. Kessler, Y. Tomita, A. Drakaki, J. Zhang, B. Simsek, G. Schwab, B. Escudier, R.J. Motzer, T.K. Choueiri, A.B. Apolo, T.B. Powles
Journal: Annals of Oncology (2021)
A case of verocytotoxin-producing Escherichia coli O157 from a private barbecue in South East England
Authors: A R Shipman, S E Jones, G Smith, B Stewart, N McCarthy
Journal: Eurosurveillance (2009)

The following case report describes a cluster of Escherichia coli O157 cases in the United Kingdom related to undercooked beef at a barbecue, resulting in an intensive care admission in France with haemolytic uraemic syndrome and highlighting the need to cook beef properly.
Antiquenching Macromolecular NIR‐II Probes with High‐Contrast Brightness for Imaging‐Guided Photothermal Therapy under 1064 nm Irradiation
Authors: Quan Cheng, Youliang Tian, Huiping Dang, Changchang Teng, Kai Xie, Dalong Yin, Lifeng Yan
Journal: Advanced Healthcare Materials (2021)

Abstract Most NIR‐II fluorescent dyes, especially polymethine cyanine, face the inevitable self‐quenching phenomenon in an aqueous solution. This unacceptable property has severely limited their application in high‐resolution biological imaging. Here, a NIR‐II macromolecular probe (MPAE) is synthesized through the structure modification of molecule probe and the covalent coupling of an amphiphilic polypeptide, which presents considerable biocompatibility and negligible systemic side effect. The molecule probe's stereo structure and the polymer's conjugation could effectively prevent the π ‐ π stacking, thereby exhibiting excellent quenching resistance in aqueous solutions (absolute QY = 0.178%). This remarkable feature endows it with deeper tissue penetration than the clinically used indocyanine green (ICG) and high contrast brightness at the tumor site for the NIR‐II fluorescence imaging. Based on the effective accumulation of tumor sites and considerable photothermal conversion efficiency (40.07%), the MPAE‐NPS presents superior antitumor efficiency on breast tumor‐bearing mice under the 1064 nm irradiation without rebound or recurrence. All these outstanding performances reveal the great promise of MPAE‐NPS in Nano‐drug delivery and imaging‐assisted photothermal therapy in the NIR‐II window.
582P Health-related quality of life (HRQoL) at final analysis of the GALAHAD study of niraparib in patients with metastatic castration-resistant prostate cancer (mCRPC) and DNA repair defects (DRD)
Authors: M.R. Smith, S.K. Sandhu, D.J. George, K.N. Chi, F. Saad, A. Thiery-Vuillemin, O. Stahl, D. Olmos, D. Danila, R. Gafanov, E. Castro, H. Moon, A.M. Joshua, G.E. Mason, B.M. Espina, Y. Liu, K.B. Bevans, A. Lopez-Gitlitz, P. Francis, K. Fizazi
Journal: Annals of Oncology (2021)
396P Resectability, resections, systemic treatment and outcomes in elderly metastatic colorectal cancer (mCRC) patients (the RAXO study)
Authors: P.J. Osterlund, L-M. Soveri, K.I. Lehtomaki, P. Halonen, E.J.T. Österlund, H. Stedt, A-M. Lamminmaki, S. Aho, T. Muhonen, A. Algars, T. Salminen, R. Kallio, E. Heerva, A. Uutela, A. Nordin, L.J. Aroviita, P. Nyandoto, I. Kellokumpu, R. Ristamaki, H. Isoniemi
Journal: Annals of Oncology (2021)
1198P Anti-ALK autoantibodies in patients with ALK positive non-small cell lung cancer (NSCLC)
Authors: C. Parisi, J.C. Benitez, H. Lecourt, F.G. Dall'Olio, M. Aldea, F. Blanc-Durand, V. Vergé, C. Quivoron, C. Naltet, P. Abdayem, P. Lavaud, M.R. Ghigna, Y. Loriot, S. De Botton, D. Planchard, F. Barlesi, J-C. Soria, V. Ribrag, L. Friboulet, B. Besse
Journal: Annals of Oncology (2021)
Abstract 9965: Proposal of a New Quantitative Assessment Method for Pulmonary Vascular Volume Using Computed Tomography
Authors: Masahito Yamashiro, Toru Sakuma, Kiyozo Morita, Kazuhiro Hashimoto
Journal: Circulation (2019)

Introduction: Quantitative assessment of the pulmonary vascular bed is the key indicator of postoperative prognosis in CHD. The pulmonary artery index (PAI; Nakata’s index) represents the PA vascul...
41P Testosterone level and severity of COVID-19 infection in ambispective cohorts: The TESTOVID study
Authors: J. Noel, A. Sabouret, E. Auclin, J.B. Arlet, B. Hermann, J.L. Diehl, J.S. Hulot, E. Messas, G. Detriche, D. Lebeaux, S. Baron, A. Blanchard, S. Brabant, B. Djobo, M. Auvray-Kuentz, D. Prie, C. Laouenan, C. Dorival, J.C. Barale, S.M. Oudard
Journal: Annals of Oncology (2021)
916P Impact of sarcopenia (S) on efficacy and toxicity of nivolumab (N) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) in TOPNIVO (T) study
Authors: L. Muratori, M. Texier, L. Mayache-Badis, F. Bidault, M. Iacob, A. Daste, J. Fayette, G. Lefebvre, E. Saada-Bouzid, S. Zanetta, C. Toullec, D. Cupissol, S. Salas, M-C. Kaminsky-Forrett, A.C. Johnson, F.R. Ferrand, A. Aupérin, J. Guigay, B. Raynard, C. Even
Journal: Annals of Oncology (2021)
Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology
Authors: Brendan Reardon, Nathanael D. Moore, Nicholas S. Moore, Eric Kofman, Saud H. AlDubayan, Alexander T. M. Cheung, Jake Conway, Haitham Elmarakeby, Alma Imamovic, Sophia C. Kamran, Tanya Keenan, Daniel Keliher, David J. Konieczkowski, David Liu, Kent W. Mouw, Jihye Park, Natalie I. Vokes, Felix Dietlein, Eliezer M. Van Allen
Journal: Nature Cancer (2021)

Abstract Tumor molecular profiling of single gene-variant (‘first-order’) genomic alterations informs potential therapeutic approaches. Interactions between such first-order events and global molecular features (for example, mutational signatures) are increasingly associated with clinical outcomes, but these ‘second-order’ alterations are not yet accounted for in clinical interpretation algorithms and knowledge bases. We introduce the Molecular Oncology Almanac (MOAlmanac), a paired clinical interpretation algorithm and knowledge base to enable integrative interpretation of multimodal genomic data for point-of-care decision making and translational-hypothesis generation. We benchmarked MOAlmanac to a first-order interpretation method across multiple retrospective cohorts and observed an increased number of clinical hypotheses from evaluation of molecular features and profile-to-cell line matchmaking. When applied to a prospective precision oncology trial cohort, MOAlmanac nominated a median of two therapies per patient and identified therapeutic strategies administered in 47% of patients. Overall, we present an open-source computational method for integrative clinical interpretation of individualized molecular profiles.
Conditioned CAR-T cells by hypoxia-inducible transcription amplification (HiTA) system significantly enhances systemic safety and retains antitumor efficacy
Authors: Huan He, Qibin Liao, Chen Zhao, Cuisong Zhu, Meiqi Feng, Zhuoqun Liu, Lang Jiang, Linxia Zhang, Xiangqing Ding, Min Yuan, Xiaoyan Zhang, Jianqing Xu
Journal: Journal for ImmunoTherapy of Cancer (2021)

Background Hypoxia is a striking feature of most solid tumors and could be used to discriminate tumors from normoxic tissues. Therefore, the design of hypoxia-conditioned Chimeric Antigen Receptor (CAR) T cells is a promising strategy to reduce on-target off-tumor toxicity in adoptive cell therapy. However, existing hypoxia-conditioned CAR-T designs have been only partially successful in enhancing safety profile but accompanied with reduced cytotoxic efficacy. Our goal is to further improve safety profile with retained excellent antitumor efficacy. Methods In this study, we designed and constructed a hypoxia-inducible transcription amplification system (HiTA-system) to control the expression of CAR in T (HiTA-CAR-T) cells. CAR expression was determined by Flow cytometry, and the activation and cytotoxicity of HiTA-CAR-T cells in vitro were evaluated in response to antigenic stimulations under hypoxic or normoxic conditions. The safety of HiTA-CAR-T cells was profiled in a mouse model for its on-target toxicity to normal liver and other tissues, and antitumor efficacy in vivo was monitored in murine xenograft models. Results Our results showed that HiTA-CAR-T cells are highly restricted to hypoxia for their CAR expression, activation and cytotoxicity to tumor cells in vitro. In a mouse model in vivo, HiTA-CAR-T cells targeting Her2 antigen showed undetectable CAR expression in all different normoxic tissues including human Her2-expresing liver, accordingly, no liver and systemic toxicity were observed; In contrast, regular CAR-T cells targeting Her2 displayed significant toxicity on human Her2-expression liver. Importantly, HiTA-CAR-T cells were able to achieve signiﬁcant tumor suppression in murine xenograft models. Conclusion Our HiTA system showed a remarkable improvement in hypoxia-restricted transgene expression in comparison with currently available systems. HiTA-CAR-T cells presented significant antitumor activities in absence of any significant liver or systemic toxicity in vivo. This approach could be also applied to design CAR-T cell targeting other tumor antigens.
241P Abemaciclib plus fulvestrant in participants with HR+/HER2- advanced breast cancer: A pooled analysis of the endocrine therapy naïve (EN) participants in MONARCH 2
Authors: J. Luis-Gonzalez Trujillo, M. Escobar Gomez, J.H. Sohn, Y-H. Im, H-C. Wang, A. Llombart Cussac, W. Zhang, N. Haddad, H. Wasserstrom, G. van Hal, G.W. Sledge
Journal: Annals of Oncology (2021)
LBA67 Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer who have progressed after prior VEGFR-targeted therapy: Updated results from the phase III COSMIC-311 trial and prespecified subgroup analyses by prior therapy
Authors: J. Capdevila, B. Robinson, S.I. Sherman, B. Jarzab, C-C. Lin, F. Vaisman, A.O. Hoff, E. Hitre, D.W. Bowles, S. Sen, P. Patel, J. Oliver, B. Keam, M.S. Brose
Journal: Annals of Oncology (2021)
33P Anti-tumor effect of vaccination with PDT-treated tumor cells
Authors: V.V. Klimenko, N.A. Verlov, V.S. Burdakov, A.A. Bogdanov, I.N. Terterov, N.A. Knyazev, V.M. Moiseyenko, A.A. Bogdanov
Journal: Annals of Oncology (2021)
AbYlink (TM): A site-selective labeling method for preclinical imaging of therapeutic antibodies
Authors: Viktoriia Postupalenko, Leo Marx, David Viertl, Natalia Gasilova, Mathilde Plantin, Nadege Gsponer, Alexandre Johanssen, Thibaut Denoel, Gerrit Hagens, Jean-Manuel Segura, Frederic Levy, Patrick Garrouste, John Prior, Margret Schottelius, Niklaus Schaefer, Origene Nyanguile
Journal: Cancer Research (2021)
124P Phase Ib-II neoadjuvant chemotherapy with docetaxel plus atezolizumab plus herceptin SC and pertuzumab (TAHP) for patients with HER2-positive stage II/III breast cancer (Neo-PATH) (KCSG BR 18-23, NCT03991878)
Authors: Y.H. Park, S-A. Im, S.H. Sim, K.J. Suh, M.H. Kim, H.K. Ahn, J.H. Jeong, J-Y. Kim, D-W. Lee, J-H. Ahn, H. Chae, K-H. Lee, J.H. Kim, K.S. Lee, J.H. Sohn, K.H. Jung
Journal: Annals of Oncology (2021)
LBA14 Neoadjuvant giredestrant (GDC-9545) + palbociclib (palbo) vs anastrozole (A) + palbo in post-menopausal women with oestrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+/HER2– eBC): Interim analysis of the randomised, open-label, phase II coopERA BC study
Authors: S.A. Hurvitz, Y.H. Park, A. Bardia, V. Quiroga, V. López-Valverde, J. Steinseifer, H.M. Moore, G. Spera, C. Xue, P.A. Fasching
Journal: Annals of Oncology (2021)
1311P The role of inflammatory biomarkers in advanced non-small cell lung cancer patients treated with chemo-immunotherapy
Authors: E. Zattarin, S. Manglaviti, E. Galli, G. Apollonio, T. Beninato, L. Mazzeo, G. Massa, A. Bottiglieri, M. Ganzinelli, C. Proto, R. Ferrara, A. Prelaj, G. Galli, A. De Toma, M. Brambilla, M. Occhipinti, M.C.C. Garassino, F.G.M. De Braud, G. Lo Russo
Journal: Annals of Oncology (2021)
1483P Cell-free DNA dominant clone allele frequency associates with poor outcomes in advanced pancreatic cancer
Authors: P.L.S. Uson Junior, G. Botrus, J. Yin, H. Dada, L. Drusbosky, U. Majeed, D. Ahn, M. Sonbol, M. Borad, T. Bekaii-Saab, K. Mody
Journal: Annals of Oncology (2021)
Health risks of extreme heat
Authors: Radhika Khosla, Anant Jani, Rafael Perera
Journal: BMJ (2021)

Record breaking heat events, once rare, are now common. 1 An extra 475 million exposures to heatwaves (that is, one person experiencing three days or more of extreme heat) were observed globally in 2019 compared with 1986-2005. 2 Clear evidence links the intensity and frequency of heat extremes to human induced global warming, which also increases the probability of compound events such as concurrent heatwaves and droughts. 3 The implications are serious: extreme heat has a substantial impact on all 17 UN sustainable development goals-including zero hunger, good health and wellbeing for all, climate action, and reduced inequalities 4 -directly affecting both people and the planet.
A multifunctional hydrogel coating to direct fibroblast activation and infected wound healing via simultaneously controllable photobiomodulation and photodynamic therapies
Authors: Ye He, Jin Leng, Ke Li, Kun Xu, Chuanchuan Lin, Zhang Yuan, Rui Zhang, Danyang Wang, Bailong Tao, Tony Jun Huang, Kaiyong Cai
Journal: Biomaterials (2021)
180P Relapse pattern after neoadjuvant treatment in early breast cancer
Authors: A. Gasol Cudos, S. Morales Murillo, O. Pallisé Subirats, F. Vilardell Villellas, D.R. Sánchez Guzman, C. Canosa Morales, J. Melé Olivé, A. Velasco Sánchez, J.F. Cordoba Ortega
Journal: Annals of Oncology (2021)
1319P Impact of bone radiotherapy on immune checkpoint inhibitors efficacy in patients with metastatic non-small cell lung cancer: A single-institution experience
Authors: G. Nnatoli, I. Facilissimo, None F. Gaspari, None D. Bongiovanni, None P. Gollini, None C. Provenza, A. Comandone
Journal: Annals of Oncology (2021)
LBA53 Sintilimab plus chemotherapy (chemo) versus chemo as first-line treatment for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (ORIENT-16): First results of a randomized, double-blind, phase III study
Authors: J. Xu, H. Jiang, Y. Pan, K. Gu, S. Cang, L. Han, Y. Shu, J. Li, J. Zhao, H. Pan, S. Luo, Y. Qin, Q. Guo, Y. Bai, Y. Ling, Y. Guo, Z. Li, Y. Liu, Y. Wang, H. Zhou
Journal: Annals of Oncology (2021)
Exercise-Induced Cardiovascular Adaptations and Approach to Exercise and Cardiovascular Disease
Authors: Matthew W. Martinez, Jonathan H. Kim, Ankit B. Shah, Dermot Phelan, Michael S. Emery, Meagan M. Wasfy, Antonio B. Fernandez, T. Jared Bunch, Peter Dean, Alfred Danielian, Sheela Krishnan, Aaron L. Baggish, Thijs M.H. Eijsvogels, Eugene H. Chung, Benjamin D. Levine
Journal: Journal of the American College of Cardiology (2021)
604P Predictive genomic biomarkers in non-metastatic castration resistant prostate cancer (nmCRPC) treated with androgen receptor pathway inhibitors (ARPi)
Authors: R. Gagnon, S.E. El Hallani, R. Lee-Ying, M.P. Kolinsky, D.J. Khalaf, S. Cook, C. Vasquez, D. Samuel, J.D. Lewis, R.M. Faridi, M. Borkar, D.Y.C. Heng, N. Alimohamed, J.D. Ruether, G.T. Gotto, A. Fairey, T.A. Bismar, S. Yip
Journal: Annals of Oncology (2021)
933P Updated results for pembrolizumab (pembro) monotherapy as first-line therapy for advanced hepatocellular carcinoma (HCC) in the phase II KEYNOTE-224 study
Authors: J-L. van Laethem, I. Borbath, M. Karwal, C. Verslype, H. Van Vlierberghe, A. Kardosh, V. Zagonel, P. Stal, D. Sarker, D. Palmer, A. Vogel, J. Edeline, S. Cattan, M. Kudo, A-L. Cheng, S. Ogasawara, A.B. Siegel, M. Chisamore, A. Wang, A. Zhu
Journal: Annals of Oncology (2021)
765P Prognosis of BRCA1 and BRCA2 ovarian cancer: Prospective follow-up data from a multidisciplinary program
Authors: P. Antunes Meireles, I.C. Oliveira, P. Rodrigues, T. Duarte, S. Santos, B. Mira, C. Bexiga, C. Pereira, A. Opinião, A.C. Luís, I. Miguel, S. Fragoso, F. Vaz
Journal: Annals of Oncology (2021)
Immune signatures underlying post-acute COVID-19 lung sequelae
Authors: I. S. Cheon, C. Li, Y. M. Son, N. P. Goplen, Y. Wu, T. Cassmann, Z. Wang, X. Wei, J. Tang, Y. Li, H. Marlow, S. Hughes, L. Hammel, T. M. Cox, E. Goddery, K. Ayasoufi, D. Weiskopf, J. Boonyaratanakornkit, H. Dong, H. Li, R. Chakraborty, A. J. Johnson, E. Edell, J. J. Taylor, M. H. Kaplan, A. Sette, B. J. Bartholmai, R. Kern, R. Vassallo, J. Sun
Journal: Science Immunology (2021)

Respiratory tissue resident–like CD8 + T cells are associated with chronic lung sequelae post-acute COVID-19.
1536P Biological processes associated with the efficacy of sunitinib plus nivolumab in soft-tissue sarcoma: Correlative studies of the IMMUNOSARC trial of Spanish (GEIS) and Italian (ISG) sarcoma groups
Authors: S. Lacerenza, D. Moura, M. Peña-Chilet, N. Hindi, J. Dopazo, P. Sanchez-Bustos, G. Grignani, J. Martinez-Trufero, A. Redondo, C. Valverde, S. Stacchiotti, A. Lopez Pousa, L. D’Ambrosio, H. Perez-Vega, P. Collini, J.A. Lopez-Martin, J. Martin Broto
Journal: Annals of Oncology (2021)
Shaping EU medicines regulation in the post COVID-19 era
Authors: Marco Cavaleri, Fergus Sweeney, Rosa Gonzalez-Quevedo, Melanie Carr
Journal: The Lancet Regional Health - Europe (2021)

The EU Medicines Regulatory Network (EMRN), comprised of the European Medicines Agency (EMA), the medicines regulatory authorities of the Member States and the European Commission (EC), is operating amid a complex crisis that has positioned regulators centre stage due to their key role in the development, approval and safety monitoring of vaccines and treatments for COVID-19. Here we consider the EMA's and EMRN's response to the pandemic and some of the early learnings that will help reshape medicines regulation in the post COVID-19 era. We also reflect on how some of these learnings will be formally followed up under revised EU legislation to extend EMA's mandate, reinforcing its role in crisis preparedness and response.
Mitophagy in the basolateral amygdala mediates increased anxiety induced by aversive social experience
Authors: Kaizheng Duan, Qinhua Gu, Ronald S Petralia, Ya-Xian Wang, Debabrata Panja, Xing Liu, Michael L Lehmann, Huiwen Zhu, Jun Zhu, Zheng Li
Journal: Neuron (2021)
Exercise‐induced changes of vital signs in adults with sickle cell disease
Authors: Solomon Johnson, Victor R. Gordeuk, Roberto Machado, J. Simon R. Gibbs, Mariana Hildesheim, Jane A. Little, Gregory J. Kato, Mark T. Gladwin, Mehdi Nouraie
Journal: American Journal of Hematology (2021)

The six-minute walk test (6MWT) has been used in patients with sickle cell disease (SCD), in conjunction with tricuspid regurgitant velocity (TRV) and plasma N-terminal pro-brain natriuretic peptide (NT-pro BNP), to assess risk of having pulmonary hypertension. Exercise-induced vital sign changes (VSCs) are predictors of clinical outcomes in other diseases. In this study, we assess the predictors and prognostic value of 6MWT VSC in adult SCD patients. Data from a multinational study of SCD patients (Treatment of Pulmonary Hypertension with Sildenafil: walk-PHaSST) were used to calculate the 6MWT VSC. Predictors of VSC were identified by a multivariable analysis, and a survival analysis was conducted by the Cox proportional hazard method. An increase in heart rate was observed in 90% of the 630 SCD adults, 77% of patients had an increase in systolic blood pressure (SBP), and 50% of patients had a decrease in oxygen saturation. TRV (odds ratio [OR] = 1.82, p = .020), absolute reticulocyte count (OR = 1.03, p < .001), and hemoglobin (OR = 0.99, p = .035) predicted oxygen desaturation ≥ 3% during the 6MWT. In the adjusted analysis, SBP increase during the 6MWT was associated with improved survival (hazards ratio = 0.3, 95% confidence interval: 0.1-0.8). Increases in heart rate and blood pressure, as well as oxygen desaturation, are common in adults with SCD during the 6MWT. VSC is associated with markers of anemia and TRV and can be used for risk stratification. Any increase in SBP during the 6MWT was associated with improved survival and may be indicative of a patient's ability to increase stroke volume.
1043P NF1 mutations and immune checkpoint inhibitor outcomes in patients with BRAF wildtype melanoma
Authors: M. Vilbert, A. Rose, L. Mantle, I. King, T. Pimentel Muniz, S. Genta, D.P. Arteaga, R. Singh, Z. Saeed Kamil, M.O. Butler, S. Saibil, A. Easson, A. Covelli, D. Hogg, A. Spreafico
Journal: Annals of Oncology (2021)